# Claire Harrison

Source: https://onco.cc/people/claire-harrison/  
OnCo record `claire-harrison` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.

## Summary

Claire Harrison was principal investigator of COMFORT-II, the European trial showing the JAK inhibitor ruxolitinib shrinks spleens and improves symptoms compared with best available therapy in myelofibrosis, which with COMFORT-I made ruxolitinib the first approved MPN therapy. She has led the MAJIC, PT-1 and RESPONSE trials in polycythaemia vera and essential thrombocythaemia and chairs the UK MPN research network.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: mpn; jak-inhibitor; uk
- Role: Professor of Myeloproliferative Neoplasms and Clinical Director of Haematology, Guy's and St Thomas' NHS Foundation Trust
- Specialisms: Myeloproliferative neoplasms; Myelofibrosis; JAK inhibitors; Clinical trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre](https://onco.cc/institutions/guys-st-thomas/)
- key papers: [COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis](https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/), [MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor](https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/)
- journals: [Blood](https://onco.cc/journals/blood/)

---
JSON: https://onco.cc/api/v1/entities/claire-harrison.json